Claims for Patent: 7,192,718

Summary for Patent: 7,192,718

Title:	Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof
Abstract:	The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.
Inventor(s):	Yamaguchi; Kyoji (Saitama, JP), Yasuda; Hisataka (Tochigi, JP), Nakagawa; Nobuaki (Tochigi, JP), Shima; Nobuyuki (Tochigi, JP), Kinosaki; Masahiko (Tochigi, JP), Tsuda; Eisuke (Tochigi, JP), Goto; Masaaki (Tochigi, JP), Yano; Kazuki (Tochigi, JP), Tomoyasu; Akihiro (Tochigi, JP), Kobayashi; Fumie (Tochigi, JP), Washida; Naohiro (Tochigi, JP), Takahashi; Ken (Tochigi, JP), Morinaga; Tomonori (Tochigi, JP), Higashio; Kanji (Saitama, JP)
Assignee:	Sankyo Co. Ltd (Tokyo, JP)
Application Number:	10/460,623
Patent Claims:	1. A method for identifying a substance which specifically binds to a molecule consisting of the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 17 and modulates bone resorption activity or osteoclastogenesis activity comprising: (a) exposing said molecule to said substance; (b) determining whether said substance binds said molecule; and (c) determining whether said substance modulates bone resorption activity or osteoclastogenesis activity of said molecule, wherein a substance which binds said molecule and modulates said activities is identified as such a substance. 2. The method of claim 1, wherein said bone resorption activity or osteoclastogenesis activity is selected from the group consisting of promotion of osteoclast differentiation and promotion of maturation from immature precursors of osteoclasts. 3. The method of claim 1, wherein said substance modulates the bone resorption activity or osteoclastogenesis activity of an animal osteoclastogenesis inhibitory factor binding molecule (OBM). 4. The method of claim 1, wherein said substance modulates the bone resorption activity or osteoclastogenesis activity of a human osteoclastogenesis inhibitory factor binding molecule (OBM). 5. The method of claim 1, wherein said substance inhibits the biological activity of an osteoclastogenesis inhibitory factor binding molecule (OBM). 6. The method of claim 1, wherein said determining whether said substance modulates the bone resorption activity or osteoclastogenesis activity of said molecule comprises testing for a reduction in tartaric acid resistant acidic phosphatase activity levels in the presence of said substance relative to an absence of said substrate. 7. The method of claim 1, wherein said determining whether said substance modulates the bone resorption activity or osteoclastogenesis activity of said molecule comprises testing for inhibition of bone resorbing activity in the presence of said substance relative to an absence of said substance. 8. The method of claim 7, wherein said testing for inhibition of bone resorbing activity comprises comparing an amount of calcium in a presence and an absence of said substance. 9. The method of claim 7, wherein said inhibition of bone resorbing activity is induced by a bone resorbing factor. 10. The method of claim 9, wherein said bone resorbing factor is selected from the group consisting of vitamin D.sub.3, prostaglandin E.sub.2, parathyroid hormone, and interleukin 1.alpha.. 11. A method for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor binding molecule (OBM) comprising the amino acid sequence of SEQ ID NO: 11 and modulates the bone resorption activity or osteoclastogenesis activity of said molecule comprising: (a) exposing said molecule to said substance; (b) determining whether said substance binds a molecule comprising the amino acid sequence of SEQ ID NO: 11; and (c) determining whether said substance modulates the bone resorption activity or osteoclastogenesis activity of said molecule, wherein a substance which binds a molecule consisting of SEQ ID NO: 17 and modulates said activities is identified as such a substance. 12. The method of claim 11, wherein said substance inhibits the bone resorption activity or osteoclastogenesis activity of said molecule. 13. The method of claim 11, wherein said bone resorption activity or osteoclastogenesis activity is selected from the group consisting of promotion of osteoclast differentiation and promotion of maturation from immature precursors of osteoclasts. 14. The method of claim 11, wherein said molecule comprising an amino acid sequence of SEQ ID NO: 11 specifically binds to an osteoclastogenesis inhibitory factor (OCIF) and inhibits the biological activity of said OCIF. 15. A method for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor binding molecule (OBM) comprising the amino acid sequence of SEQ ID NO: 17 and modulates the bone resorption activity or osteoclastogenesis activity of said OBM molecule comprising: (a) exposing said molecule to said substance; (b) determining whether said substance binds a molecule comprising the amino acid sequence of SEQ ID NO: 17; and (c) determining whether said substance modulates the bone resorption activity or osteoclastogenesis activity of said molecule, wherein a substance which binds a molecule consisting of SEQ ID NO: 17 and modulates said activities is identified as such a substance. 16. The method of claim 15, wherein said substance inhibits the bone resorption activity or osteoclastogenesis activity of said molecule. 17. The method of claim 15, wherein said bone resorption activity or osteoclastogenesis activity is selected from the group consisting of promotion of osteoclast differentiation and promotion of maturation from immature precursors of osteoclasts. 18. The method of claim 15, wherein said molecule comprising the amino acid sequence of SEQ ID NO: 17 specifically binds to an osteoclastogenesis inhibitory factor (OCIF) and inhibits the biological activity of said OCIF.

Details for Patent 7,192,718

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2017-04-15